


NG25 trihydrochloride

Cat. No.:	HY-15434A
CAS No.:	2108554-00-1
Molecular Formula:	C ₂₉ H ₃₃ Cl ₃ F ₃ N ₅ O ₂
Molecular Weight:	646.96
Target:	MAP3K; MAP4K
Pathway:	MAPK/ERK Pathway
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

NG25 trihydrochloride is a dual TAK1 and MAP4K2 inhibitor (IC₅₀: 149 nM and 21.7 nM respectively). NG25 sensitizes the breast cancer cells to Doxorubicin (HY-15142A), and enhances apoptosis. NG25 trihydrochloride can be used for research of various cancers^{[1][2]}.

CUSTOMER VALIDATION

- Nat Cell Biol. 2017 Oct;19(10):1248-1259.
- Cell Death Differ. 2019 Dec;26(12):2520-2534.
- Cell Death Dis. 2022 Apr 30;13(4):421.
- Oncogene. 2017 Oct 5;36(40):5620-5630.
- J Cell Biol. 2018 Aug 6;217(8):2727-2742.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Tan L, et al. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96.

[2]. Wang Z, et al. TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells. Sci Rep. 2016 Sep 7;6:32737.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA